End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era
Author:
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
http://www.tandfonline.com/doi/pdf/10.1586/era.11.164
Reference42 articles.
1. Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
2. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
3. Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
4. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Letter concerning “Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival”: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma;Neuro-Oncology;2023-05-12
2. Translational Gap in Glioma Research;Anti-Cancer Agents in Medicinal Chemistry;2014-08-25
3. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO);Journal of Cancer Research and Clinical Oncology;2013-02-12
4. Electric fields for the treatment of glioblastoma;Expert Review of Neurotherapeutics;2012-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3